AIM: Tumour necrosis factor inhibitors (TNFi) have revolutionized the management of moderate to severe ulcerative colitis (UC) since their approval for UC in 2005. However, many patients ultimately require surgery with ileal pouch-anal anastomosis (IPAA). Development of de novo Crohn's disease (CD) following IPAA is an increasingly common and devastating complication, sometimes progressing to pouch failure. The aim of this study was to evaluate the association of preoperative TNFi exposure and the development of de novo CD after IPAA. METHOD: A prospective single-centre inflammatory bowel disease (IBD) registry was searched for consecutive patients with UC undergoing IPAA during a 25-year period ending July 2018. Patients with preoperative CD or IBD-unclassified were excluded. De novo CD was diagnosed upon endoscopic evidence of five or more mucosal ulcers proximal to the ileal pouch any time after surgery and/or pouch fistula occurring more than three months after ileostomy closure. RESULTS: The study cohort consisted of 400 patients with a median follow-up of 44.0 (IQR 11-113) months. Sixty-two (16%) patients developed de novo CD 28.0 (IQR 6-67) months following ileostomy closure. Survival analysis of TNFi era patients revealed a significant increase in de novo CD risk in those with preoperative TNFi exposure. Multivariable proportional hazards modelling revealed two independent predictors for de novo CD development: older age was protective (HR 0.89 per 5-year increase; P = 0.009) and preoperative TNFi exposure was hazardous (HR 2.10; P = 0.011). CONCLUSION: This prospective study is the first to suggest an association between preoperative TNFi exposure and the development of de novo CD.
AIM: Tumour necrosis factor inhibitors (TNFi) have revolutionized the management of moderate to severe ulcerative colitis (UC) since their approval for UC in 2005. However, many patients ultimately require surgery with ileal pouch-anal anastomosis (IPAA). Development of de novo Crohn's disease (CD) following IPAA is an increasingly common and devastating complication, sometimes progressing to pouch failure. The aim of this study was to evaluate the association of preoperative TNFi exposure and the development of de novo CD after IPAA. METHOD: A prospective single-centre inflammatory bowel disease (IBD) registry was searched for consecutive patients with UC undergoing IPAA during a 25-year period ending July 2018. Patients with preoperative CD or IBD-unclassified were excluded. De novo CD was diagnosed upon endoscopic evidence of five or more mucosal ulcers proximal to the ileal pouch any time after surgery and/or pouch fistula occurring more than three months after ileostomy closure. RESULTS: The study cohort consisted of 400 patients with a median follow-up of 44.0 (IQR 11-113) months. Sixty-two (16%) patients developed de novo CD 28.0 (IQR 6-67) months following ileostomy closure. Survival analysis of TNFi era patients revealed a significant increase in de novo CD risk in those with preoperative TNFi exposure. Multivariable proportional hazards modelling revealed two independent predictors for de novo CD development: older age was protective (HR 0.89 per 5-year increase; P = 0.009) and preoperative TNFi exposure was hazardous (HR 2.10; P = 0.011). CONCLUSION: This prospective study is the first to suggest an association between preoperative TNFi exposure and the development of de novo CD.
Authors: A Gustavsson; G Järnerot; E Hertervig; I Friis-Liby; L Blomquist; P Karlén; C Grännö; M Vilien; M Ström; H Verbaan; P M Hellström; A Magnuson; J Halfvarson; C Tysk Journal: Aliment Pharmacol Ther Date: 2010-08-18 Impact factor: 8.171
Authors: Bo Shen; Victor W Fazio; Feza H Remzi; Aaron Brzezinski; Ana E Bennett; Rocio Lopez; Jeffrey P Hammel; Jean-Paul Achkar; Charles L Bevins; Ian C Lavery; Scott A Strong; Conor P Delaney; Wendy Liu; Marlene L Bambrick; Kerry K Sherman; Bret A Lashner Journal: Clin Gastroenterol Hepatol Date: 2006-01 Impact factor: 11.382
Authors: Bo Shen; Feza H Remzi; Jeffrey P Hammel; Bret A Lashner; Charles L Bevins; Ian C Lavery; Jan Wehkamp; Victor W Fazio Journal: Inflamm Bowel Dis Date: 2009-02 Impact factor: 5.325
Authors: Thomas Hui; Carol Landers; Eric Vasiliauskas; Maria Abreu; Marla Dubinsky; Konstantinos A Papadakis; Joanne Price; Ying-Chao Lin; Yang Huiying; Stephan Targan; Phillip Fleshner Journal: Dis Colon Rectum Date: 2005-06 Impact factor: 4.585
Authors: Paul Rutgeerts; William J Sandborn; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Suzanne Travers; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel Journal: N Engl J Med Date: 2005-12-08 Impact factor: 91.245
Authors: Gunnar Järnerot; Erik Hertervig; Ingalill Friis-Liby; Lars Blomquist; Per Karlén; Christer Grännö; Mogens Vilien; Magnus Ström; Ake Danielsson; Hans Verbaan; Per M Hellström; Anders Magnuson; Bengt Curman Journal: Gastroenterology Date: 2005-06 Impact factor: 22.682
Authors: William J Sandborn; Paul Rutgeerts; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Jiandong Lu; Kevin Horgan; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel Journal: Gastroenterology Date: 2009-07-28 Impact factor: 22.682
Authors: Joshua M Braveman; David J Schoetz; Peter W Marcello; Patricia L Roberts; John A Coller; John J Murray; Lawrence C Rusin Journal: Dis Colon Rectum Date: 2004-10 Impact factor: 4.585